ArticleClinical and experimental immunology2014

A novel protocol allowing oral delivery of a protein complement inhibitor that subsequently targets to inflamed colon mucosa and ameliorates murine colitis.

M Elvington et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.